Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Operating Leases (2022 - 2026)

Lucid Diagnostics filings provide 4 years of Operating Leases readings, the most recent being $1.8 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 31.42% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 31.42% decrease, with the full-year FY2025 number at $1.8 million, down 31.42% from a year prior.
  • Operating Leases hit $1.8 million in Q4 2025 for Lucid Diagnostics, down from $2.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.9 million in Q3 2024 to a low of $464000.0 in Q3 2023.
  • Median Operating Leases over the past 4 years was $1.8 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Operating Leases: plummeted 76.83% in 2023 and later surged 517.67% in 2024.
  • Lucid Diagnostics' Operating Leases stood at $1.0 million in 2022, then increased by 25.84% to $1.3 million in 2023, then skyrocketed by 103.37% to $2.7 million in 2024, then plummeted by 31.42% to $1.8 million in 2025.
  • The last three reported values for Operating Leases were $1.8 million (Q4 2025), $2.0 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.